P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016
Published Aug 10, 2016
35 pages — Published Aug 10, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016, provides in depth analysis on P27 (Negative Regulatory Factor or Nef) targeted pipeline therapeutics.

The report provides comprehensive information on the P27 (Negative Regulatory Factor or Nef) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in P27 (Negative Regulatory Factor or Nef) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for P27 (Negative Regulatory Factor or Nef)
- The report reviews P27 (Negative Regulatory Factor or Nef) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in P27 (Negative Regulatory Factor or Nef) targeted therapeutics and enlists all their major and minor projects
- The report assesses P27 (Negative Regulatory Factor or Nef) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to P27 (Negative Regulatory Factor or Nef) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for P27 (Negative Regulatory Factor or Nef)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic init

  
Source:
Document ID
GMDHC0451TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
P27 (Negative Regulatory Factor or Nef) Overview61
Therapeutics Development73
  P27 (Negative Regulatory Factor or Nef) Products under Development by Stage of Development71
  P27 (Negative Regulatory Factor or Nef) Products under Development by Therapy Area81
  P27 (Negative Regulatory Factor or Nef) Products under Development by Indication91
P27 (Negative Regulatory Factor or Nef) Pipeline Products Glance102
  Late Stage Products101
  Early Stage Products111
P27 (Negative Regulatory Factor or Nef) Products under Development by Companies122
P27 (Negative Regulatory Factor or Nef) Products under Development by Universities/Institutes142
P27 (Negative Regulatory Factor or Nef) Therapeutics Assessment166
  Assessment by Monotherapy/Combination Products161
  Assessment by Mechanism of Action171
  Assessment by Route of Administration182
  Assessment by Molecule Type202
P27 (Negative Regulatory Factor or Nef) Drug Profiles229
  HIV vaccine Drug Profile221
  HIV vaccine Drug Profile231
  HIV vaccine 1 Drug Profile241
  HIV-1 vaccine 1 Drug Profile251
  HIV-1 vaccine 5 Drug Profile261
  Monoclonal Antibody Conjugate to Inhibit Gag, Nef, Pol for HIV Drug Profile271
  MVATG-17401 Drug Profile281
  Small Molecules to Inhibit Nef for HIV-1 Infections Drug Profile291
  Tatbeclin-1 Drug Profile301
P27 (Negative Regulatory Factor or Nef) Dormant Projects312
P27 (Negative Regulatory Factor or Nef) Featured News &Press Releases331
  Jan 02, 2015: HIV vaccines should avoid viral target cells, primate model study suggests331
Appendix342
  Methodology341
  Coverage341
  Secondary Research341
  Primary Research341
  Expert Panel Validation341
  Contact Us341
  Disclaimer351

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016" Aug 10, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/P27-Negative-Regulatory-Factor-or-Nef-Pipeline-Review-H2-2016-2088-16373>
  
APA:
Global Markets Direct - Market Research. (2016). P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Aug 10, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/P27-Negative-Regulatory-Factor-or-Nef-Pipeline-Review-H2-2016-2088-16373>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.